In addition to T2D and CVDs (64), CDKN2B-AS1 has been shown to be aberrantly expressed in various malignancies, idiopathic pulmonary fibrosis, endometriosis, inflammatory bowel disease, and primary open-angle glaucoma and to participate in the progression of lipids, carbohydrate metabolism, and inflammation regulation (65), which is likely to serve as a promising therapeutic target or prognostic biomarker in multiple human diseases. This evidence concerns the gene CDKN2B and idiopathic pulmonary fibrosis.